Log in

NASDAQ:SBOTStellar Biotechnologies Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$4.44
MA: $59,624.23
$298,098.00
52-Week Range N/A
Volume28,516 shs
Average Volume2.95 million shs
Market Capitalization$14.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.
Read More
Stellar Biotechnologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBOT
CUSIPN/A
Phone805-488-2800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210,000.00
Book Value$2.12 per share

Profitability

Net Income$-5,030,000.00
Net Margins-1,782.64%

Miscellaneous

Employees25
Market Cap$14.60 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SBOT News and Ratings via Email

Sign-up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter.

Stellar Biotechnologies (NASDAQ:SBOT) Frequently Asked Questions

How were Stellar Biotechnologies' earnings last quarter?

Stellar Biotechnologies Inc (NASDAQ:SBOT) issued its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.05. The biotechnology company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.11 million. Stellar Biotechnologies had a negative net margin of 1,782.64% and a negative return on equity of 51.12%. View Stellar Biotechnologies' earnings history.

When did Stellar Biotechnologies' stock split? How did Stellar Biotechnologies' stock split work?

Shares of Stellar Biotechnologies reverse split on Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 4th 2018. An investor that had 100 shares of Stellar Biotechnologies stock prior to the reverse split would have 14 shares after the split.

Has Stellar Biotechnologies been receiving favorable news coverage?

News stories about SBOT stock have trended extremely negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Stellar Biotechnologies earned a news impact score of -4.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutStellar Biotechnologies.

Who are some of Stellar Biotechnologies' key competitors?

What other stocks do shareholders of Stellar Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stellar Biotechnologies investors own include XOMA (XOMA), Nexgen Energy (NXE), Anavex Life Sciences (AVXL), Eyepoint Pharmaceuticals (EYPT), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), Statoil (STO), Abraxas Petroleum (AXAS) and Carrizo Oil & Gas (CRZO).

Who are Stellar Biotechnologies' key executives?

Stellar Biotechnologies' management team includes the following people:
  • Mr. Frank R. Oakes, Chairman, Pres & CEO (Age 69)
  • Ms. Kathi Niffenegger CPA, CFO & Corp. Sec. (Age 62)
  • Mr. Gary Koppenjan, Sr. Director of Investor Relations & Communications
  • Brando Lincicum, Exec. Director of Aquaculture and Facility Operations

What is Stellar Biotechnologies' stock symbol?

Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."

How big of a company is Stellar Biotechnologies?

Stellar Biotechnologies has a market capitalization of $0.00 and generates $210,000.00 in revenue each year. The biotechnology company earns $-5,030,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Stellar Biotechnologies employs 25 workers across the globe.

What is Stellar Biotechnologies' official website?

The official website for Stellar Biotechnologies is www.stellarbiotechnologies.com.

How can I contact Stellar Biotechnologies?

Stellar Biotechnologies' mailing address is 332 EAST SCOTT STREET, PORT HUENEME CA, 93041. The biotechnology company can be reached via phone at 805-488-2800 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.